

The Cancer Cachexia Action Network presents a seminar by:

Dr. Wenwei Hu

Leukemia Inhibiting Factor (LIF), its role in tumorigenesis and Cancer Cachexia

Abstract: Cancer cachexia, a multifactorial disease characterized by weight loss, muscle wasting, and fat browning, is challenging due to the complexity of its metabolic disorder and the lack of effective therapies, calling for a better understanding of its underlying mechanisms. Leukemia inhibitory factor (LIF), a multi-functional cytokine, has been suggested to be a cachexia-inducing factor. We established a cachexia mouse model with conditionally inducible LIF expression that can help us to study cachexia and the contribution of LIF to it.



Date: Friday, December 16, 2022 **Time:** 8:00 a.m.-10:00 a.m. (ET)

For a meeting invite please email: Sean Parnell at srp87@cinj.rutgers.edu

Dr. Hu is a Professor in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey at Rutgers University. She received her PhD from Zhejiang University School of Medicine for research on mutagenesis induced by chemical carcinogen. Dr. Hu completed postdoctoral training in NYU Medical School focusing on DNA damage and repair before she moved to the University of Medicine and Dentistry of New Jersey continuing her postdoctoral training with Dr. Arnold Levine studying p53 and its signaling pathway. Since 2009, Dr. Hu has been a faculty member at Rutgers Cancer Institute of New Jersey. A major research interest of Dr. Hu's group is to study the function and regulation of tumor suppressor p53, which in turn impacts tumorigenesis. Her group's work also made important contributions toward understanding the mechanisms of mutant p53 accumulation and gain of oncogenic activity in tumors. In addition, Dr. Hu studies the function of LIF, a cytokine that is a p53 target in tumorigenesis.

Funded by



